O A Khan

Summary

Affiliation: Wayne State University
Country: USA

Publications

  1. ncbi request reprint Comparative assessment of immunomodulating therapies for relapsing-remitting multiple sclerosis
    Omar Khan
    Department of Neurology, Multiple Sclerosis Center, Wayne State University School of Medicine, D University Health Center, 4201 St Antoine, Detroit, MI 48201, USA
    CNS Drugs 16:563-78. 2002
  2. ncbi request reprint Can clinical outcomes be used to detect neuroprotection in multiple sclerosis?
    Omar Khan
    Multiple Sclerosis Center and Neuroimaging Laboratory, Department of Neurology, Wayne State University School of Medicine, Detroit, MI 48201, USA
    Neurology 68:S64-71; discussion S91-6. 2007
  3. doi request reprint Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis
    Omar Khan
    Department of Neurology and Multiple Sclerosis Center, Wayne State University School of Medicine, Detroit, MI 48201, USA
    Ann Neurol 73:705-13. 2013
  4. doi request reprint Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: results of a five-year brain MRI study
    Omar Khan
    MR Image Analysis Laboratory, Department of Neurology, Wayne State University School of Medicine, Detroit, MI 48201, USA
    J Neurol Sci 312:7-12. 2012
  5. doi request reprint Chronic cerebrospinal venous insufficiency and multiple sclerosis
    Omar Khan
    Multiple Sclerosis Center, Department of Neurology, Wayne State University School of Medicine, 4201 St Antoine, Detroit, MI 48323, USA
    Ann Neurol 67:286-90. 2010
  6. doi request reprint What can be learned from open direct comparative trials in multiple sclerosis?
    Omar Khan
    School of Medicine, Wayne State University, Detroit, MI, USA
    J Neurol Sci 277:S25-8. 2009
  7. doi request reprint Long-term study of brain 1H-MRS study in multiple sclerosis: effect of glatiramer acetate therapy on axonal metabolic function and feasibility of long-Term H-MRS monitoring in multiple sclerosis
    Omar Khan
    Multiple Sclerosis Clinical Research Center, Department of Neurology, The Detroit Medical Center, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    J Neuroimaging 18:314-9. 2008
  8. ncbi request reprint A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis
    O A Khan
    Department of Neurology, Wayne State University School of Medicine, Detroit, MI, USA
    Eur J Neurol 8:141-8. 2001
  9. ncbi request reprint Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis
    Omar Khan
    Department of Neurology, Multiple Sclerosis Center, Wayne State University School of Medicine, Detroit, MI 48201, USA
    Mult Scler 11:646-51. 2005
  10. ncbi request reprint A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy
    O A Khan
    Multiple Sclerosis Center, Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    Mult Scler 7:349-53. 2001

Collaborators

Detail Information

Publications28

  1. ncbi request reprint Comparative assessment of immunomodulating therapies for relapsing-remitting multiple sclerosis
    Omar Khan
    Department of Neurology, Multiple Sclerosis Center, Wayne State University School of Medicine, D University Health Center, 4201 St Antoine, Detroit, MI 48201, USA
    CNS Drugs 16:563-78. 2002
    ..In a pharmaceutical environment with an estimated worldwide market of $US2.5 billion annually for RRMS, comparative studies are understandably provocative, but at the same time provide meaningful information to clinicians and patients...
  2. ncbi request reprint Can clinical outcomes be used to detect neuroprotection in multiple sclerosis?
    Omar Khan
    Multiple Sclerosis Center and Neuroimaging Laboratory, Department of Neurology, Wayne State University School of Medicine, Detroit, MI 48201, USA
    Neurology 68:S64-71; discussion S91-6. 2007
    ..However, a consensus definition of "neuroprotection" applicable to MS needs to be established before such a tool can be validated and put to use...
  3. doi request reprint Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis
    Omar Khan
    Department of Neurology and Multiple Sclerosis Center, Wayne State University School of Medicine, Detroit, MI 48201, USA
    Ann Neurol 73:705-13. 2013
    ..To assess the efficacy and safety of glatiramer acetate (GA) 40mg administered 3× weekly (tiw) compared with placebo in patients with relapsing-remitting multiple sclerosis (RRMS)...
  4. doi request reprint Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: results of a five-year brain MRI study
    Omar Khan
    MR Image Analysis Laboratory, Department of Neurology, Wayne State University School of Medicine, Detroit, MI 48201, USA
    J Neurol Sci 312:7-12. 2012
    ..To compare the long-term effect of disease-modifying therapies (DMT) on brain volume loss in relapsing-remitting MS (RRMS) patients...
  5. doi request reprint Chronic cerebrospinal venous insufficiency and multiple sclerosis
    Omar Khan
    Multiple Sclerosis Center, Department of Neurology, Wayne State University School of Medicine, 4201 St Antoine, Detroit, MI 48323, USA
    Ann Neurol 67:286-90. 2010
    ..At present, invasive and potentially dangerous endovascular procedures as therapy for patients with MS should be discouraged until such studies have been completed, analyzed, and debated in the scientific arena...
  6. doi request reprint What can be learned from open direct comparative trials in multiple sclerosis?
    Omar Khan
    School of Medicine, Wayne State University, Detroit, MI, USA
    J Neurol Sci 277:S25-8. 2009
    ....
  7. doi request reprint Long-term study of brain 1H-MRS study in multiple sclerosis: effect of glatiramer acetate therapy on axonal metabolic function and feasibility of long-Term H-MRS monitoring in multiple sclerosis
    Omar Khan
    Multiple Sclerosis Clinical Research Center, Department of Neurology, The Detroit Medical Center, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    J Neuroimaging 18:314-9. 2008
    ..These data support the long-term effect of GA on maintaining axonal metabolic function and protection from sublethal injury as well as the feasibility of employing brain (1)H-MRS in long-term investigative studies in MS...
  8. ncbi request reprint A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis
    O A Khan
    Department of Neurology, Wayne State University School of Medicine, Detroit, MI, USA
    Eur J Neurol 8:141-8. 2001
    ..Despite some limitations of the study design, the results provide helpful clinical information regarding the relative efficacy of each therapy in mildly affected treatment-naïve RRMS patients...
  9. ncbi request reprint Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis
    Omar Khan
    Department of Neurology, Multiple Sclerosis Center, Wayne State University School of Medicine, Detroit, MI 48201, USA
    Mult Scler 11:646-51. 2005
    ..These results support an in situ effect of GA therapy inside the CNS and suggest potential neuroprotective effects of GA...
  10. ncbi request reprint A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy
    O A Khan
    Multiple Sclerosis Center, Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    Mult Scler 7:349-53. 2001
    ..106) who did not show a significant reduction. Despite limitations of the study design, the results provide helpful clinical information regarding the relative efficacy of each therapy in mildly affected treatment naive RRMS patients...
  11. ncbi request reprint Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy
    O A Khan
    Multiple Sclerosis Center, Department of Neurology, Wayne State University School of Medicine, Detroit, USA
    Mult Scler 7:185-8. 2001
    ..Therapy with CTX was well tolerated. CTX may be of benefit in MS patients who experience rapid clinical worsening and are resistant to conventional therapy...
  12. ncbi request reprint Intercaudate nucleus ratio as a linear measure of brain atrophy in multiple sclerosis
    C Caon
    Multiple Sclerosis Center, Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan, USA
    Neurology 60:323-5. 2003
    ..67; p = 0.0001) and disease duration (r = 0.32; p < 0.01). Intercaudate ratio appears to be a reliable and reproducible linear measure of brain atrophy and correlates with disability and disease duration in MS...
  13. ncbi request reprint Glatiramer acetate therapy for multiple sclerosis: a review
    Jai Perumal
    Wayne State University School of Medicine, Department of Neurology, 8D UHC, Detroit, MI 48201, USA
    Expert Opin Drug Metab Toxicol 2:1019-29. 2006
    ....
  14. pmc Multiple sclerosis susceptibility alleles in African Americans
    B A Johnson
    Department of Neurology, University of California, San Francisco, CA 94143, USA
    Genes Immun 11:343-50. 2010
    ..None of the tested variants showed results that were statistically inconsistent with the effects established in whites. The results are consistent with shared disease genetic mechanisms among individuals of European and African ancestry...
  15. doi request reprint Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician
    Aaron Boster
    The Multiple Sclerosis Clinical Research Center, Department of Neurology, Wayne State University School of Medicine, and The Detroit Medical Center, Detroit, MI 48201, USA
    Lancet Neurol 7:173-83. 2008
    ..This Review describes the use of intense immunosuppressant drugs and natalizumab in patients with rapidly worsening MS and provides clinicians with guidelines for the use of these drugs in this patient group...
  16. doi request reprint Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study
    Aaron Boster
    Department of Neurology, Wayne State University School of Medicine, Detroit, MI 48201, USA
    Arch Neurol 66:593-9. 2009
    ..To identify clinical and magnetic resonance imaging (MRI) features that distinguish progressive multifocal leukoencephalopathy (PML) from relapsing-remitting multiple sclerosis (RRMS)...
  17. ncbi request reprint Acute transverse myelitis with normal brain MRI : long-term risk of MS
    Jui Perumal
    Multiple Sclerosis Center, Dept of Neurology, Wayne State University School of Medicine, Detroit, MI, USA
    J Neurol 255:89-93. 2008
    ..To investigate the long-term risk of developing MS in patients presenting with acute transverse myelitis (ATM) and normal brain MRI scans at onset...
  18. doi request reprint A phase 3 trial of extended release oral dalfampridine in multiple sclerosis
    Andrew D Goodman
    Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Ann Neurol 68:494-502. 2010
    ..The current study was designed to confirm efficacy and further define safety and pharmacodynamics...
  19. pmc Characterizing iron deposition in multiple sclerosis lesions using susceptibility weighted imaging
    E Mark Haacke
    Department of Radiology, Wayne State University, Detroit, Michigan 48201, USA
    J Magn Reson Imaging 29:537-44. 2009
    ..To investigate whether the variable forms of putative iron deposition seen with susceptibility weighted imaging (SWI) will lead to a set of multiple sclerosis (MS) lesion characteristics different than that seen in conventional MR imaging...
  20. doi request reprint Modification of Multiple Sclerosis Phenotypes by African Ancestry at HLA
    Bruce A C Cree
    Department of Neurology, University of California San Francisco, USA
    Arch Neurol 66:226-33. 2009
    ....
  21. ncbi request reprint Uncoupling the roles of HLA-DRB1 and HLA-DRB5 genes in multiple sclerosis
    Stacy J Caillier
    Department of Neurology, University of California, San Francisco, CA 94143, USA
    J Immunol 181:5473-80. 2008
    ..The data underscore the power of the African American MS dataset to identify disease genes by association in a region of high linkage disequilibrium...
  22. doi request reprint Fitness to drive in multiple sclerosis: awareness of deficit moderates risk
    Kelly A Ryan
    Wayne State University, Detroit, MI 48202, USA
    J Clin Exp Neuropsychol 31:126-39. 2009
    ..The findings have implications for interventions with persons with MS who drive...
  23. pmc Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans
    Jorge R Oksenberg
    Department of Neurology, University of California at San Francisco, San Francisco, CA 94143 0435, USA
    Am J Hum Genet 74:160-7. 2004
    ..This finding is unlikely to be solely explained by admixture, since a substantial proportion of the susceptibility chromosomes from African American patients with MS displayed haplotypes consistent with an African origin...
  24. ncbi request reprint Predictors of subjective well-being among individuals with multiple sclerosis
    Kelly A Ryan
    Wayne State University, Detroit, MI 48202, USA
    Clin Neuropsychol 21:239-62. 2007
    ..The findings present a unique view of SWB among individuals with MS in the absence of acute exacerbation of the illness...
  25. ncbi request reprint Interferon-beta therapy for MS: the dilemma of having choices
    Omar Khan
    J Neurol Sci 222:1. 2004
  26. ncbi request reprint Clinical inquiries. What nonpharmacological treatments are effective against common nongenital warts?
    Holly Abernethy
    Shenandoah Valley Family Practice Residency, Department of Family Medicine, Virginia Commonwealth University, Front Royal, VA USA
    J Fam Pract 55:801-2. 2006
    ..CO2 laser, photodynamic therapy, pulsed dye laser (PDL), and Er:Yag laser therapies may also be effective for recalcitrant warts (SOR: C, based on observational cohort studies)...
  27. ncbi request reprint A whole-genome admixture scan finds a candidate locus for multiple sclerosis susceptibility
    David Reich
    Department of Genetics, Harvard Medical School, Boston, Massachusetts, USA
    Nat Genet 37:1113-8. 2005
    ..We describe here the first high-powered admixture scan, focusing on 605 African American cases and 1,043 African American controls, and report a locus on chromosome 1 that is significantly associated with multiple sclerosis...
  28. ncbi request reprint Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis
    Paul O'Connor
    Division of Neurology, St Michael s Hospital, 30 Bond Street, Suite 3007S Shuter Wing, Toronto, Ontario, Canada
    Mult Scler 11:568-72. 2005
    ..In a six month, phase II clinical trial of patients with relapsing MS, natalizumab significantly reduced the formation of new gadolinium-enhanced (Gd+) lesions and the number of clinical relapses...